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Abstract
Background: Aspirin esterase (AE) activity can account for part of aspirin pharmacokinetics in the circulation,
possibly being associated with the impairment of aspirin effectiveness as an inhibitor of platelet aggregation.
Aims: The study was aimed at investigating the correlations of serum AE activity with cholinesterase (ChE) and
metabolic variables in healthy subjects in comparison to subjects with type 2 diabetes mellitus (T2DM).
Methods: In cardiovascular disease-free T2DM subjects and healthy controls, the AE activity levels and/or the
correlation patterns between AE and the other variables were analyzed.
Results: Neither AE nor ChE activities were higher in the subjects with T2DM. Serum AE activity strongly correlated
with ChE as well as glucose/lipids variables such as total cholesterol and triglyceride in healthy subjects, while the
correlations between AE and glucose/lipids variables were not present in T2DM subjects.
Conclusions: These data may reflect the pathophysiological changes between healthy and T2DM subjects. Our
data may thus provide the basis for future studies to unravel the mechanisms.
Background
Aspirin (acetylsalicylic acid), by virtue of its antipyretic,
analgesic, anti-inflammatory and anti-platelet actions, is
one of the most widely employed drugs in the preven-
tion of cardiovascular disease. While its prophylactic use
against athero-thrombosis is well-documented, the opti-
mal dose that confers maximal anti-platelet action with-
out increased risk of bleeding remains to be determined
[1,2]. Serum aspirin esterase (AE) activity may account
for part of aspirin pharmacokinetics and has been pro-
posed as one source of variation in aspirin effectiveness
[3].
Type 2 diabetes mellitus (T2DM) is a common health
problem associated with cardiovascular disease, with an
increasing incidence worldwide [4]. One study has
recently reported an increased level of AE activity in
patients with T2DM, and it has been suggested that this
may be modified by lipoprotein-cholesterol metabolism
in these patients [5]. In addition, serum cholinesterase
(ChE) has shown a tight correlation with AE and an
association with the dyslipoproteinemia of the metabolic
syndrome [5,6]. However, these relationships remain yet
to be fully established. We thus conducted this study to
shed further light on the correlation of AE with ChE
and metabolic variables, including lipids, in healthy sub-
jects in comparison to subjects with T2DM.
Methods
In this case-control observational study, twenty-seven
subjects with T2DM, who were on stable metabolic con-
trol and treated with hypoglycemic agents, were enrolled
from our outpatient population consulting the Showa
University Northern Yokohama Hospital, Japan. Twenty
control subjects in the study were recruited from an
asymptomatically healthy population with no history of
diabetes mellitus. All subjects were free of acute illness,
and those with a history of cardiovascular disease and
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were excluded. The study was approved by the institu-
tional review board of Showa University and each sub-
ject gave informed consent.
A fasting blood sample was obtained by venipuncture
and dry tubes were used for serum or for plasma
sodium citrate (5 mmol/L final concentration) or
sodium EDTA (5 mmol/L final concentration) were
added as anti-coagulants. Blood was centrifuged at 800
× g at 4°C for 15-minutes, and separated serum or
plasma was immediately analyzed. Serum lipid panels
such as total cholesterol, high-density lipoprotein (HDL)
cholesterol and triglyceride, as well as serum albumin
and plasma glucose, were enzymatically measured.
Hemoglobin A1c (HbA1c) were measured by an HPLC
method. Serum AE activity was measured kinetically by
a modification of the procedure described by Sorensen
[7]. The reagent buffer contains Tris-HCl (0.6 mol/L)
and CaCl2 (0.4 mol/L) in pH 7.6-7.7. Substrate is 555
mmol/L acetylsalicylic acid (1 g in 10 mL 100% ethanol
for the stock solution). The method was modified in our
laboratory toward a more precise kinetic method
adapted to 96-well microplates. Briefly, 15 μLs a m p l e
(serum) were pipetted per well (in duplicate) into a 96-
well UV flat bottom plate (Thermo-8404). Stock sub-
strate solution was diluted 1 in 50 into reagent buffer,
and then 200 μL of this final substrate solution was
added per well using a multi-channel pipette. The runs
were blanked against reagent (to control for sponta-
neous hydrolysis of acetylsalicylic acid). Plates were
placed in a temperature-controlled plate reader Spectra-
Max UV with SOFTmax PRO software (Molecular
Devices, Sunnyvale, CA, USA). Samples were kinetically
read at 300 nm at 37°C for 15-minutes. Results are
expressed in nmol of acetylsalicylic acid hydrolyzed per
minute and per milliliter (nmol/mL/min). The intra-
assay CV (coefficient of variation) is 4%, and the inter-
assay CV is 5%. Additionally, serum ChE (butyrylcholi-
nesterase) activity was determined using the standard
p r o c e d u r ea sp r e v i o u s l yd e s c r i b e d[ 8 ] .T h ea s s a yu s e s
the thiol ester butyrilcholine. ChE hydrolyses the ester
to produce thiocholine and acetate. The thiocholine in
turn reduces the dithiobis-nitrobenzoic acid (DTNB) lib-
erating nitrobenzoate, which absorbs at 405 nm. Briefly,
5 μL sample (serum) were pipetted per well (in dupli-
cate) into a 96-well plate. The buffer (100 mmol/L
NaHPO4 in pH 7.0-8.0), substrate (7.5 mmol/L butyr-
ylthiocholine iodide in H2O) and DTNB (10 mmol/L 5,
5’-dithiobis-2-nitrobenzoic acid (3.96 mg/mL) in 100
mmol/L buffer containing 1.5 mg NaH2CO4)w e r e
mixed to give a final concentration of 0.1 mmol/L
butyrylthiocholine. The runs were blanked against
reagent, and plates were placed in a temperature con-
trolled plate reader SpectraMax UV. Samples were
kinetically read at 405 nm at 37°C for 3-minutes. Results
are expressed in U/L. The intra-assay and inter-assay
CVs are 0.8 and 6.3%, respectively.
Data were expressed as mean ± standard deviation or
median (interquartile range). For the between-group dif-
ferences, unpaired t-test or c
2-test was used. For the
correlations between AE and the other variables, we
used single and multiple linear regression models. Con-
sidering the basic confounders and the co-linearity
between the measured variables (in particular, glucose/
lipids and ChE with each other: e.g., ChE vs. total cho-
lesterol, r = 0.57; triglyceride, r = 0.76; fasting glucose, r
= 0.45), the two adjusted-linear regression models (age-
and gender-adjusted model, as well as age-, gender- and
body mass index-adjusted model) were set out. Because
triglyceride and AE had a skewed distribution, the values
were logarithm-transformed in analyzing. A p value <
0.05 was considered significant.
Results
The subject characteristics are listed in Table 1.
Although the group of T2DM had significantly higher
levels of fasting glucose and HbA1c as well as signifi-
cantly lower levels of HDL cholesterol than the control
group, AE and ChE levels did not significantly differ
between the two groups. As shown in Table 2, in single
correlation tests (Model 1), in the control group, AE
was significantly and positively correlated with fasting
glucose, total cholesterol and triglyceride, respectively.
While AE was inversely correlated with HDL choles-
terol, this correlation did not reach a statistical signifi-
cance level. In contrast, in the group of T2DM, there
were no significant correlations between these variables
and AE. A significant positive correlation between AE
and ChE was observed in both groups of T2DM and
control, while the correlation level appeared somewhat
high in the control group. The respective correlation
patterns in the group of T2DM and control remained to
be similarly continued, even after adjusting for age and
gender (Model 2), as well as age, gender and body mass
index (Model 3).
Discussion
We found that serum AE activity did not differ between
T2DM subjects and healthy subjects. This is in contrast
with a previous report showing an increased AE activity
in patients with T2DM [5]. The inconsistency may
partly stem from the differences in studied populations
including ethnicity [9] and/or their respective degree of
metabolic control. Our studied population seemed to be
in good metabolic control as shown by their body mass
index, HbA1c and lipids levels. Since T2DM is a syn-
drome with a wide spectrum of metabolic disturbances
and etiologies [10,11], our results can not completely
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T2DM are aspirin-resistant due to increased AE activity,
while our data do not support them. Further controlled
studies in various populations are needed to solve this
controversy. Second, we also showed that serum ChE
levels did not obviously differ between the subjects with
T2DM and healthy subjects, but they had a very strong
correlation with AE activity. This may be in line with
t h ep r e v i o u sw o r k[ 7 ] .I tm u s tb en o t e dt h a t ,a s
described in the Methods section, the two enzyme activ-
ities are measured with different substrates and detec-
tion methods, therefore the correlation is not due to an
analytical bias. One of the possible mechanisms to
explain the correlation is the fact that aspirin is hydro-
lyzed in the circulation by two distinct pathways of a
s p o n t a n e o u sp H - d e p e n d e n th y d r o l y s i sa sw e l la sa n
enzymatic hydrolysis by plasma and erythrocyte
esterases, and that the plasma system consists, in part,
of butyrylcholinesterase as well as albumin [12].
Thirdly, more interestingly, when we correlated AE
activity in healthy subjects with the other variables and
even when controlling for confounders, we found a sig-
nificant close correlation of fasting glucose, total choles-
terol and triglyceride with AE activity, respectively. This
is the first new finding in our work. In contrast to the
correlation between glucose and AE, the reason for a
non-significant correlation between HbA1c and AE
remains unclear. This may be related to the fact that
fasting plasma glucose is a one-point measure while
HbA1c is reflective of mean glucose condition over a
period of 2-3 months. Possibly, our data imply that
short-term changes in glucose, which may be regulated
Table 1 Clinical characteristics of type 2 diabetic subjects and control subjects
Variables Controls (N = 20) Type 2 Diabetics (N = 27) p value
Age, years 60.1 ± 14.3 55.9 ± 10.0 0.24
Men/women, n 8/12 18/9 0.07
Body mass index, kg/m
2 22.1 ± 3.7 22.8 ± 2.6 0.46
Fasting glucose, mmol/L 5.41 ± 0.79 9.13 ± 3.66 < 0.0001**
HbA1c, % 5.0 ± 0.4 7.6 ± 1.3 < 0.0001**
Total cholesterol, mmol/L 5.54 ± 1.10 5.28 ± 0.96 0.48
Triglyceride, mmol/L 1.04 (0.84-1.45) 2.11 (1.93-2.34) 0.13
HDL cholesterol, mmol/L 1.76 ± 0.41 1.40 ± 0.38 0.006**
Albumin, μmol/L 629 ± 27 605 ± 44 0.07
ChE, U/L 319 ± 73 360 ± 74 0.07
Aspirin esterase (nmol/mL/min) 39.2 (32.5-48.7) 41.6 (37.1-46.5) 0.66
HbA1c: hemoglobin A1c, HDL: high-density lipoprotein, ChE: cholinesterase. Data are presented as mean ± standard deviation, median (interquartile range) or
number. Triglyceride and aspirin esterase were log-transformed because of their skewed distribution in the statistical analyses. Significance level (t-test or c
2-test
between the group with controls and type 2 diabetes): ** p < 0.01.
Table 2 Correlation patterns for aspirin esterase to the other variables in type 2 diabetic subjects and in control
subjects
Controls Type 2 diabetics
Variables Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
Age, years -0.11(0.64) - - 0.01(0.96) - -
Gender, men 0.10(0.69) - - -0.07(0.74) - -
Body mass index, kg/m
2 0.08(0.76) 0.07(0.80) - 0.28(0.32) 0.42(0.25) -
Fasting glucose, mmol/L 0.54(0.014)* 0.65(0.006)** 0.65(0.008)** 0.16(0.44) 0.15(0.48) -0.04(0.85)
HbA1c, % -0.18(0.45) -0.16(0.61) -0.14(0.66) 0.09(0.67) 0.07(0.75) 0.03(0.93)
Total cholesterol, mmol/L 0.58(0.007)** 0.67(0.004)** 0.69(0.006)** -0.06(0.76) -0.07(0.74) -0.21(0.56)
Triglyceride, mmol/L 0.85(< 0.0001)** 0.85(< 0.0001)** 0.86(< 0.0001)** -0.07(0.72) -0.06(0.77) -0.16(0.61)
HDL cholesterol, mmol/L -0.43(0.09) -0.50(0.12) -0.56(0.13) -0.04(0.86) -0.25(0.29) -0.08(0.86)
Albumin, μmol/L 0.44(0.06) 0.43(0.07) 0.43(0.10) 0.03(0.90) 0.09(0.71) -0.03(0.94)
ChE, U/L 0.78(< 0.0001)** 080(< 0.0001)** 0.80(0.001)** 0.70(< 0.0001)** 0.70(< 0.0001)** 0.75(0.02)*
HbA1c: hemoglobin A1c, HDL: high-density lipoprotein, ChE: cholinesterase. Data are presented as the single linear regression coefficients (p value) in Model 1,
the age- and gender-adjusted linear regression coefficients (p value) in Model 2 and the age-, gender- and body mass index-adjusted linear regression
coefficients (p value) in Model 3, respectively. Triglyceride and aspirin esterase were log-transformed because of their skewed distribution in the single and
multiple linear regression analyses. Significance level: * p < 0.05, ** p < 0.01.
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while adaptations resulting from long-term adjustments
can act differently for both analytes.
Moreover, surprisingly, the strong association between
AE and glucose/lipids variables we observed in our con-
trol population was not present in subjects with T2DM.
The present data suggest that the metabolic changes
specifically found in T2DM (i.e., higher glycemic excur-
sions, lower HDL cholesterol concentrations) [10,11]
may cancel the link between glucose/lipids and AE
activity. This second new finding of our work is puzzling
and therefore interesting; the mechanisms remain to be
explored.
This study had potential limitations such as a small
sample-size design. However, given the clear and signifi-
cant findings, this may lay the ground for further studies
on the pathophysiology of the link between AE and
metabolic variables.
Conclusions
In summary, the present study shows that serum AE
activity strongly correlates with ChE as well as glucose/
lipids variables in healthy subjects. Neither AE nor ChE
activities increase in the subjects with T2DM, and the
correlations between AE and glucose/lipids variables are
not present in these subjects. These data may open the
field for future studies to unravel the mechanisms.
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